Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity

Muscle Nerve. 2011 May;43(5):665-70. doi: 10.1002/mus.21933.

Abstract

Introduction: Pompe disease (glycogen storage disease type II, acid maltase deficiency) is caused by deficiency of lysosomal acid α-glucosidase (GAA). A few late-onset patients have been reported with skin fibroblast GAA activity levels of <2%.

Methods: We measured GAA activity in skin fibroblasts from 101 patients with late-onset Pompe disease. Whenever possible, we performed Western blot analysis and correlated the results with GAA activity and GAA gene mutations.

Results: Thirteen patients (13%) had skin fibroblast GAA activity of <1% of normal. Although there was wide genetic heterogeneity, none of these patients carried the common late-onset mutation c.-32-13T > G. We performed Western blot on 11 patients with <1% GAA activity. All produced GAA protein that was at lower levels and/or was abnormally processed.

Discussion: There is no common mutation associated with <1% GAA activity in late-onset Pompe disease patients. Most patients produce unprocessed forms of GAA protein compared with patients with higher GAA activity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Aged
  • Blotting, Western / methods
  • Child
  • Enzyme Activation / genetics
  • Glycogen Storage Disease Type II / enzymology*
  • Glycogen Storage Disease Type II / epidemiology
  • Glycogen Storage Disease Type II / genetics*
  • Humans
  • Middle Aged
  • Mutation / genetics
  • Protein Modification, Translational / genetics*
  • Young Adult
  • alpha-Glucosidases / genetics*
  • alpha-Glucosidases / metabolism*

Substances

  • GAA protein, human
  • alpha-Glucosidases